Want to see HK:0455 full AI Analyst Report?
0455 Stock Chart & Stats
HK$0.13
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$0.13
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$0.08 - HK$0.22
Previous CloseN/A
Volume4.00K
Average Volume (3M)84.94K
Market Cap
HK$223.60M
Enterprise ValueHK$344.93
Total Cash (Recent Filing)HK$64.81M
Total Debt (Recent Filing)HK$132.66M
Price to Earnings (P/E)―
Beta0.42
Next Earnings
Aug 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding2,150,041,700
10 Day Avg. Volume115,400
30 Day Avg. Volume84,945
Financial Highlights & Ratios
PEG Ratio-0.28
Price to Book (P/B)0.61
Price to Sales (P/S)0.86
P/FCF Ratio99.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Manageable LeverageDebt levels are moderate with debt-to-equity around 0.19–0.29, giving the company breathing room on interest and refinancing risk. A conservative leverage profile supports resilience across cycles, preserving capacity to fund working capital or R&D without immediate solvency pressure.
Healthy Gross MarginsGross margins in the low- to mid-40s indicate structural product-level profitability and pricing power versus peers. Even with some compression, sustained mid-40% gross margins provide a durable cushion to absorb SG&A and R&D, aiding a path to operating leverage if revenue stabilizes.
Return To Positive Cash FlowResuming positive operating cash flow and modest free cash flow in 2025 marks a structural inflection from multi-year outflows. If management sustains cash generation, the company can self-fund operations and reduce reliance on external financing, improving long-term financial flexibility.
Bears Say
Persistent LossesChronic net losses and widening negative margins (net margin about -21.7% in 2025) erode retained earnings and constrain reinvestment. Persistent unprofitability risks capital depletion, restricts strategic options, and makes sustainable returns to shareholders difficult without a clear path to consistent profitability.
Declining RevenueFalling top-line reduces the ability to leverage fixed costs and undermines operating leverage. Structural revenue decline complicates recovery of margins and limits scale benefits in manufacturing and R&D, making margin restoration and cash-flow consistency harder over a multi-quarter horizon.
Eroding Equity And Negative ROEShrinking shareholder equity and persistent negative ROE reflect cumulative losses that weaken the capital base. This erosion limits the firm's buffer against shocks, raises future financing or dilution risk, and impairs credibility with creditors and partners over the medium term.
Tianda Pharmaceuticals Ltd. News
0455 FAQ
What was Tianda Pharmaceuticals Ltd.’s price range in the past 12 months?
Tianda Pharmaceuticals Ltd. lowest stock price was HK$0.08 and its highest was HK$0.21 in the past 12 months.
What is Tianda Pharmaceuticals Ltd.’s market cap?
Tianda Pharmaceuticals Ltd.’s market cap is HK$223.60M.
When is Tianda Pharmaceuticals Ltd.’s upcoming earnings report date?
Tianda Pharmaceuticals Ltd.’s upcoming earnings report date is Aug 10, 2026 which is today.
How were Tianda Pharmaceuticals Ltd.’s earnings last quarter?
Tianda Pharmaceuticals Ltd. released its earnings results on Mar 26, 2026. The company reported -HK$0.017 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Tianda Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Tianda Pharmaceuticals Ltd.’s price is currently Overvalued.
Does Tianda Pharmaceuticals Ltd. pay dividends?
Tianda Pharmaceuticals Ltd. pays a N/A dividend of HK$0.003 which represents an annual dividend yield of N/A. See more information on Tianda Pharmaceuticals Ltd. dividends here
What is Tianda Pharmaceuticals Ltd.’s EPS estimate?
Tianda Pharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tianda Pharmaceuticals Ltd. have?
Tianda Pharmaceuticals Ltd. has 2,150,041,700 shares outstanding.
What happened to Tianda Pharmaceuticals Ltd.’s price movement after its last earnings report?
Tianda Pharmaceuticals Ltd. reported an EPS of -HK$0.017 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Tianda Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in HK:0455
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tianda Pharmaceuticals Ltd.
Founded in 1992 and headquartered in Central, Hong Kong, Tianda Pharmaceuticals Limited operates as an investment holding company and a subsidiary of Tianda Group Limited. The firm, which changed its name from Tianda Holdings Limited in September 2012, focuses on the research, development, manufacturing, and distribution of a wide array of pharmaceutical, biotechnology, and healthcare products. Its commercial reach extends across Mainland China, Hong Kong, and Australia. The company's diverse portfolio includes traditional Chinese medicines, chemical drugs, biological products, and medical appliances. These offerings target numerous therapeutic areas, such as cardio-cerebrovascular health, pediatric care, anti-flu and respiratory conditions, anti-infection, detoxification, and urological disorders. Health supplements are specifically marketed under the "Herb Valley" and "Tuokang" brand names. Furthermore, Tianda Pharmaceuticals is involved in the wholesale and retail of Chinese herbal medicines, traditional Chinese medicine (TCM) decoction pieces, and other Chinese medicinal products, provides Chinese medical services, and trades agricultural by-products.
Technical Analysis
Extrawell Pharmaceutical Holdings Limited
―
Wai Yuen Tong Medicine Holdings Limited
―
PuraPharm Corp. Ltd.
―
Dawnrays Pharmaceutical Holdings Ltd.
―
Pak Fah Yeow International Limited
―